BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 30699063)

  • 1. Re: "The Efficacy and Safety of the Fixed Combination of Brinzolamide 1% and Brimonidine 0.2% in Normal Tension Glaucoma: An 18-Month Retrospective Study" by Jin and Lee (J. Ocul. Pharmacol. Ther. 34:274-279, 2018).
    Chua PY; Clare G; Leslie T
    J Ocul Pharmacol Ther; 2019; 35(1):3-4. PubMed ID: 30699063
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to Chua et al. re: "The Efficacy and Safety of the Fixed Combination of Brinzolamide 1% and Brimonidine 0.2% in Normal Tension Glaucoma: An 18-Month Retrospective Study".
    Jin SW
    J Ocul Pharmacol Ther; 2019; 35(1):5. PubMed ID: 30699062
    [No Abstract]   [Full Text] [Related]  

  • 3. The Efficacy and Safety of the Fixed Combination of Brinzolamide 1% and Brimonidine 0.2% in Normal Tension Glaucoma: An 18-Month Retrospective Study.
    Jin SW; Lee SM
    J Ocul Pharmacol Ther; 2018 Apr; 34(3):274-279. PubMed ID: 29297751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension.
    Aung T; Laganovska G; Hernandez Paredes TJ; Branch JD; Tsorbatzoglou A; Goldberg I
    Ophthalmology; 2014 Dec; 121(12):2348-55. PubMed ID: 25064721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation.
    Lusthaus JA; Goldberg I
    Expert Opin Drug Saf; 2017 Sep; 16(9):1071-1078. PubMed ID: 28656780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brinzolamide/brimonidine: a review of its use in patients with open-angle glaucoma or ocular hypertension.
    Greig SL; Deeks ED
    Drugs Aging; 2015 Mar; 32(3):251-60. PubMed ID: 25732405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension.
    Day DG; Hollander DA
    Curr Med Res Opin; 2008 May; 24(5):1435-42. PubMed ID: 18402717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%.
    Katz G; Dubiner H; Samples J; Vold S; Sall K
    JAMA Ophthalmol; 2013 Jun; 131(6):724-30. PubMed ID: 23579344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension.
    Gandolfi SA; Lim J; Sanseau AC; Parra Restrepo JC; Hamacher T
    Adv Ther; 2014 Dec; 31(12):1213-27. PubMed ID: 25430900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brinzolamide plus brimonidine for the treatment of glaucoma: an update.
    Chew SK; Skalicky SE; Goldberg I
    Expert Opin Pharmacother; 2014 Nov; 15(16):2461-71. PubMed ID: 25267543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
    Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
    Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
    Bournias TE; Lai J
    Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%.
    Feldman RM; Tanna AP; Gross RL; Chuang AZ; Baker L; Reynolds A; Prager TC;
    Ophthalmology; 2007 Jul; 114(7):1248-54. PubMed ID: 17509688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs and persistence of brimonidine versus brinzolamide in everyday glaucoma care: an analysis conducted on the UK General Practitioner Research Database.
    Lafuma A; Laurendeau C; Berdeaux G
    J Med Econ; 2008; 11(3):485-97. PubMed ID: 19450100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of different combinations of maximum medical therapy for lowering intraocular pressure in primary open angle glaucoma: 12-month retrospective consecutive case series.
    Joh HJ; Jin SW
    Jpn J Ophthalmol; 2019 Jul; 63(4):322-327. PubMed ID: 31115761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 24-Hour Effects of Brinzolamide/Brimonidine Fixed Combination and Timolol on Intraocular Pressure and Ocular Perfusion Pressure.
    Seibold LK; DeWitt PE; Kroehl ME; Kahook MY
    J Ocul Pharmacol Ther; 2017 Apr; 33(3):161-169. PubMed ID: 28129020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized Trial of Fixed-Dose Combination Brinzolamide 1%/Brimonidine 0.2% as Adjunctive Therapy to Travoprost 0.004.
    Feldman RM; Katz G; McMenemy M; Hubatsch DA; Realini T
    Am J Ophthalmol; 2016 May; 165():188-97. PubMed ID: 26940161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letter to the editor regarding Gerente, V.M., Biondi, A.C., Barbosa, C.P., et al. Effect of brimonidine tartrate 0.15% on scotopic pupil: controlled trial. J. Ocul. Pharmacol. Ther 23:476-480, 2007.
    Khanani AM; Brown SM
    J Ocul Pharmacol Ther; 2008 Jun; 24(3):364-5; author reply 366. PubMed ID: 18476806
    [No Abstract]   [Full Text] [Related]  

  • 19. Brinzolamide-brimonidine fixed combination to prevent intraocular pressure elevation after neodymium:YAG laser posterior capsulotomy.
    Makri OE; Plotas P; Tsapardoni FN; Georgakopoulos CD
    J Cataract Refract Surg; 2018 Apr; 44(4):514-515. PubMed ID: 29705011
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of 24-hour intraocular pressure reduction obtained with brinzolamide/timolol or brimonidine/timolol fixed-combination adjunctive to travoprost therapy.
    Konstas AG; Holló G; Haidich AB; Mikropoulos DG; Giannopoulos T; Voudouragkaki IC; Paschalinou E; Konidaris V; Samples JR
    J Ocul Pharmacol Ther; 2013 Sep; 29(7):652-7. PubMed ID: 23550916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.